$ALXN (Alexion Pharmaceuticals, Inc.)

$ALXN {{ '2015-11-19T15:30:25+0000' | timeago}} • SEC

During 3Q15, $ALXN entered into a new agreement with Lonza whereby Lonza will construct a new manufacturing facility dedicated to $ALXN at their existing Portsmouth, New Hampshire facility. Under this agreement $ALXN will make certain payments during the construction of the new manufacturing facility and annual payments for ten years thereafter.

$ALXN {{ '2017-09-14T20:51:47+0000' | timeago}} • Announcement

Biopharmaceutical company $ALXN named Paul Friedman to its board of directors. Friedman had served as President and CEO of Incyte Corp. from 2001 to 2014. He succeeds Douglas Norby, who retired after serving on Alexion's board for 18 years. The company said Alvin Parven has decided not to stand for re-election as director.

$ALXN {{ '2017-09-12T13:18:41+0000' | timeago}} • Announcement

$ALXN has charted out a re-alignment plan, with its refocused corporate strategy. The initiative is expected to deliver annual pre-tax savings of about $270MM (GAAP) and $250MM (non-GAAP) by 2019. The restructuring will reduce the company's workforce by 20%. The total pre-tax restructuring expenses are expected to be between $340MM and $440MM.

$ALXN {{ '2017-08-24T19:55:21+0000' | timeago}} • Announcement

$ALXN said John Orloff has been appointed Head of Research and Development. Anne-Marie Law has joined the company as Chief Human Resources Officer and Indrani Franchini has joined as Chief Compliance Officer. All appointments are effective June 5, 2017, and the officers will report to CEO, Ludwig Hantson.

$ALXN {{ '2017-08-21T14:02:22+0000' | timeago}} • Announcement

Pharma firm $ALXN obtained approval from the European Commission for extension of the indication for Soliris, a medication for ailments affecting the immune system, to include treatment of refractory generalized myasthenia gravis. The approval was granted based on clinical data from a phase-3 REGAIN study and long-term open-label extension study.

$ALXN {{ '2017-08-15T20:45:14+0000' | timeago}} • Announcement

$ALXN announced that the United States Patent and Trademark Office (USPTO) has issued three new patents for Soliris. These will expire in 2027. The company is pursuing corresponding patent applications in other regions and countries, including Europe and Japan.

$ALXN {{ '2017-08-10T13:34:59+0000' | timeago}} • Announcement

$ALXN and Sema4 announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine $ALXN's rare disease SmartPanel analytics with Sema4's proven success in next-generation sequencing and genomic interpretation.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$CRL {{ '2017-07-05T12:50:22+0000' | timeago}} • Announcement

$CRL appointed $ALXN EVP Dr Martin Mackay to its BoD.  As a member of the board, he will serve on the Corporate Governance and Nominating Committee and the Science and Technology Committee.

$ALXN {{ '2017-06-23T12:15:29+0000' | timeago}} • Announcement

$ALXN said it received positive opinion from the Committee for Medicinal Products for Human Use to extend the therapeutic indication for Soliris to include the treatment of refractory generalized myasthenia gravis in patients who are ‘anti-acetylcholine receptor antibody-positive’. A final decision from the European Commission is expected in 3Q17.

$ALXN {{ '2017-06-13T21:27:41+0000' | timeago}} • Announcement

$ALXN appointed Paul Clancy as CFO effective July 31, 2017. Clancy will succeed Dave Anderson, who will continue to serve as CFO until July 31, 2017. To ensure a smooth transition, Anderson will then become a Senior Advisor to the CEO and will remain with the company until the end of August.

$ALXN {{ '2017-06-01T20:48:22+0000' | timeago}} • Announcement

$ALXN announced key additions to its executive leadership team effective June 5, 2017. Reporting to CEO Ludwig Hantson will be: John Orloff, M.D., EVP, Head of Research & Development, Anne-Marie Law, EVP, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., EVP, Chief Compliance Officer.

$ALXN {{ '2017-05-23T13:38:35+0000' | timeago}} • Announcement

$ALXN said Martin Mackay, EVP, Head of Research & Development will be retiring at the end of 2017. A search is also underway for a new Head of R&D with SpencerStuart. Clare Carmichael, EVP, Chief Human Resources Officer, will be leaving to pursue new opportunities effective June 1, 2017. Recruiting is underway for a new Head of Human Resources.

$ALXN {{ '2017-05-23T13:37:23+0000' | timeago}} • Announcement

$ALXN appointed Brian Goff as Chief Commercial Officer, effective June 1, 2017. Goff succeeds Carsten Thiel who is leaving to pursue new opportunities effective June 1, 2017. CFO Dave Anderson will resign his position at the end of August. A search for a new CFO is underway with SpencerStuart.

$ALXN {{ '2017-05-16T11:17:52+0000' | timeago}} • Announcement

$ALXN and The Rady Children's Institute for Genomic Medicine have announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the institute's genomic research expertise with Alexion data science and bioinformatics capabilities.

$ALXN {{ '2017-04-27T16:48:39+0000' | timeago}} • Webcast

$ALXN continues to face challenge in Latin America and expects that to continue in 2017. The company has faced significant setbacks in its attempts to expand Soliris' label in Latin America. The timing of bulk orders, access challenges in Latin America and the impact of ALXN1210 study recruitment will impact 2Q17 and 3Q17 results, said the company.

$ALXN {{ '2017-04-27T14:21:39+0000' | timeago}} • Infographic

$ALXN Alexion Pharmaceuticals Earnings AlphaGraphics: Q1 2017 highlights

$ALXN {{ '2017-04-27T11:43:38+0000' | timeago}} • Announcement

$ALXN reiterated its FY17 total revenue guidance $3.40-3.50Bil. The company increased its GAAP EPS to $2.80-3.20, from $2.55 to $3.05 and non-GAAP EPS to $5.10-5.30, from $5.00-5.25.

$ALXN {{ '2017-04-27T11:39:42+0000' | timeago}} • Announcement

Drugmaker $ALXN reported 85% growth in its 1Q17 earnings, helped by increased revenues. Net income was $170MM, or $0.75 per share, compared to $92MM, or $0.41MM during 1Q16. Revenues rose 24% YoY to $870MM. Excluding items, $ALXN earned $1.38 per share.

Recent Transcripts

EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
IMGN (ImmunoGen, Inc.)
Friday, July 28 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
KERX (Keryx Biopharmaceuticals Inc.)
Thursday, July 27 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like